PMID- 26938083
OWN - NLM
STAT- MEDLINE
DCOM- 20161027
LR  - 20201226
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 16
IP  - 5
DP  - 2016
TI  - Prospect and progress of personalized peptide vaccinations for advanced cancers.
PG  - 689-98
LID - 10.1517/14712598.2016.1161752 [doi]
AB  - INTRODUCTION: The field of cancer immunotherapy has made dramatic progress in the 
      past 20 years, in part due to the identification of numerous tumor-associated 
      antigens (TAAs). We have developed a novel immunotherapeutic approach called the 
      personalized peptide vaccine (PPV), in which a maximum of four human leukocyte 
      antigen (HLA)-matched vaccine peptides are selected based on the pre-existing 
      host immunity before vaccination. AREAS COVERED: This review describes recent 
      progress in the use of PPV for various types of advanced cancer. EXPERT OPINION: 
      Although various approaches for therapeutic cancer immunotherapies, including 
      peptide-based vaccines, have been developed and clinically examined, the diverse 
      and heterogeneous characteristics of tumor cells and host immunity seem to limit 
      their therapeutic efficacy. Selection of suitable peptide vaccines for individual 
      patients based on the pre-existing host immunity before vaccination could resolve 
      this limitation and could be a rational approach for developing effective cancer 
      vaccines.
FAU - Sakamoto, Shinjiro
AU  - Sakamoto S
AD  - a Research Center for Innovative Cancer Therapy , Kurume University , Kurume , 
      Japan.
AD  - b Cancer Vaccine Center , Kurume University , Kurume , Japan.
AD  - c Department of Molecular and Internal Medicine School of Medicine, Graduate 
      School of Biomedical and Health Sciences , Hiroshima University , Hiroshima , 
      Japan.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - a Research Center for Innovative Cancer Therapy , Kurume University , Kurume , 
      Japan.
FAU - Yamada, Akira
AU  - Yamada A
AD  - a Research Center for Innovative Cancer Therapy , Kurume University , Kurume , 
      Japan.
FAU - Itoh, Kyogo
AU  - Itoh K
AD  - b Cancer Vaccine Center , Kurume University , Kurume , Japan.
FAU - Sasada, Tetsuro
AU  - Sasada T
AD  - b Cancer Vaccine Center , Kurume University , Kurume , Japan.
AD  - d Kanagawa Cancer Center Research Institute , Yokohama , Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160321
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Peptides)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/*therapy
MH  - Peptides/therapeutic use
MH  - Precision Medicine/methods
MH  - Vaccination
MH  - Vaccines, Subunit/therapeutic use
OTO - NOTNLM
OT  - Advanced cancer
OT  - biomarker
OT  - cancer immunotherapy
OT  - cancer vaccine
OT  - clinical trial
OT  - peptide epitope
OT  - personalized peptide vaccine
EDAT- 2016/03/05 06:00
MHDA- 2016/11/01 06:00
CRDT- 2016/03/04 06:00
PHST- 2016/03/04 06:00 [entrez]
PHST- 2016/03/05 06:00 [pubmed]
PHST- 2016/11/01 06:00 [medline]
AID - 10.1517/14712598.2016.1161752 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2016;16(5):689-98. doi: 10.1517/14712598.2016.1161752. 
      Epub 2016 Mar 21.